Stocktoria
Alaunos Therapeutics, Inc. TCRT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2004-08-20
Alaunos Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5,000 | $10,000 | $5,000 | $2.9M | $398,000 |
| R&D expense | $1.4M | $362,000 | $16.3M | $25.0M | $49.6M |
| Operating income | -$4.2M | -$4.8M | -$34.3M | -$35.1M | -$77.5M |
| Interest expense | — | — | $1.9M | $3.2M | $1.2M |
| Income tax | $0 | — | — | — | — |
| Net income | -$4.2M | -$4.7M | -$4.7M | -$37.7M | -$78.8M |
| EPS (diluted) | $-2.20 | $-2.92 | $-21.97 | $-2.61 | $-0.37 |
| Operating cash flow | -$2.9M | -$5.0M | -$30.1M | -$29.2M | -$61.5M |
| Free cash flow | -$3.0M | -$5.0M | -$30.3M | -$29.4M | -$64.8M |
| Cash & equivalents | $1.4M | $1.1M | $6.1M | $39.1M | $76.1M |
| Total assets | $3.0M | $2.8M | $8.3M | $64.9M | $94.9M |
| Total liabilities | $813,000 | $692,000 | $2.0M | $26.4M | $36.8M |
| Shareholders' equity | $2.2M | $2.1M | $6.3M | $38.6M | $58.1M |
Source: SEC EDGAR filings · CIK 0001107421 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.